Faculty Opinions recommendation of Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.

Kinase Inhibitors ◽

Real Life ◽

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study

Experimental Hematology ◽

10.1016/j.exphem.2018.08.006 ◽

2018 ◽

Vol 67 ◽

pp. 41-48 ◽

Cited By ~ 13

Author(s):

Maël Heiblig ◽

Delphine Rea ◽

Marie-Lorraine Chrétien ◽

Aude Charbonnier ◽

Philippe Rousselot ◽

...

Keyword(s):

Observational Study ◽

Tyrosine Kinase ◽

Kinase Inhibitors ◽

Real Life ◽

Extranodal marginal zone lymphoma arising in a patient with chronic myelogenous leukemia on long-term tyrosine kinase inhibitors

Leukemia & Lymphoma ◽

10.3109/10428194.2013.811581 ◽

2013 ◽

Vol 55 (3) ◽

pp. 715-717 ◽

Cited By ~ 3

Author(s):

Xiangdong Xu ◽

Anjum Hassan

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitors ◽

Marginal Zone ◽

Marginal Zone Lymphoma ◽

Myelogenous Leukemia ◽

Extranodal Marginal Zone Lymphoma

Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees

Leukemia & Lymphoma ◽

10.1080/10428194.2020.1855340 ◽

2020 ◽

pp. 1-15

Author(s):

Eric J. Chow ◽

David R. Doody ◽

Jennifer J. Wilkes ◽

Laura K. Becker ◽

Shasank Chennupati ◽

...

Keyword(s):

Adverse Events ◽

Tyrosine Kinase ◽

Health Plan ◽

Real World ◽

Kinase Inhibitors ◽

Clinical and prognostic significance of 3q26 rearrangements and other chromosome 3 abnormalities in chronic myelogenous leukemia in era of tyrosine kinase inhibitors

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2015.07.067 ◽

2015 ◽

Vol 15 ◽

pp. S32-S33

Author(s):

Wei Wang ◽

Jorge Cortes ◽

Pei Lin ◽

Michael Beaty ◽

Di Ai ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitors ◽

Prognostic Significance ◽

Myelogenous Leukemia ◽

Chromosome 3

Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors

Oncology Reviews ◽

10.1007/s12156-009-0004-9 ◽

2009 ◽

Vol 3 (1) ◽

pp. 59-70

Author(s):

Michael G. Martin ◽

John F. DiPersio ◽

Geoffrey L. Uy

Keyword(s):

Targeted Therapy ◽

Tyrosine Kinase ◽

Kinase Inhibitors ◽

Myelogenous Leukemia ◽

Duration Of Response

Blast Phase in Chronic Myelogenous Leukemia Is Skewed Toward Unusual Blast Types in Patients Treated With Tyrosine Kinase Inhibitors

American Journal of Clinical Pathology ◽

10.1309/ajcpwex5yy4phscn ◽

2015 ◽

Vol 143 (1) ◽

pp. 105-119 ◽

Cited By ~ 5

Author(s):

Yang Shi ◽

Andrew J. Rand ◽

Jennifer H. Crow ◽

Joseph O. Moore ◽

Anand S. Lagoo

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitors ◽

Myelogenous Leukemia ◽

Blast Phase

Unfavorable outcome of chronic myelogenous leukemia in adolescent and young adults treated with tyrosine kinase inhibitors

International Journal of Hematology ◽

10.1007/s12185-015-1840-y ◽

2015 ◽

Vol 102 (3) ◽

pp. 342-348 ◽

Cited By ~ 6

Author(s):

Masatoshi Sakurai ◽

Takehiko Mori ◽

Daiki Karigane ◽

Keiichi Tozawa ◽

Eri Matsuki ◽

...

Keyword(s):

Young Adults ◽

Tyrosine Kinase ◽

Kinase Inhibitors ◽

Unfavorable Outcome ◽

Myelogenous Leukemia ◽

Adolescent And Young Adults

Cross Skin Reactivity to Tyrosine Kinase Inhibitors in a Patient with Chronic Myelogenous Leukemia

Journal of Cancer Therapy ◽

10.4236/jct.2013.47130 ◽

2013 ◽

Vol 04 (07) ◽

pp. 1141-1144

Author(s):

V. Broshtilova ◽

M. Balabanova

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitors ◽

Myelogenous Leukemia ◽

Skin Reactivity

Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients

Journal of Managed Care & Specialty Pharmacy ◽

10.18553/jmcp.2020.26.12.1494 ◽

2020 ◽

Vol 26 (12) ◽

pp. 1494-1504

Author(s):

Donna R Rivera ◽

Lindsey Enewold ◽

Michael J Barrett ◽

Matthew P Banegas ◽

Kelly K Filipski ◽

...

Keyword(s):

Elderly Patients ◽

Tyrosine Kinase ◽

Kinase Inhibitors ◽

Population Based ◽

Myelogenous Leukemia ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Chronic myelogenous leukemia in the era of tyrosine kinase inhibitors: Are there barriers to ideal care?

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e18046 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e18046-e18046

Author(s):

Isabelle Phuong Le ◽

Anand B. Karnad ◽

Christos Fountzilas ◽

Yuanyuan Liang ◽

Alex V. Mejia ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitors ◽